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Abstract
Aims/hypothesis The aim of this work was to map the number of prescribed drugs over age, sex and area-based socioeconomic
deprivation, and to examine the association between the number of drugs and particular high-risk drug classes with adverse health
outcomes among a national cohort of individuals with type 1 diabetes.
Methods Utilising linked healthcare records from the population-based diabetes register of Scotland, we identified 28,245
individuals with a diagnosis of type 1 diabetes on 1 January 2017. For this population, we obtained information on health status,
predominantly reflecting diabetes-related complications, and information on the total number of drugs and particular high-risk
drug classes prescribed. We then studied the association of these baseline-level features with hospital admissions for falls,
diabetic ketoacidosis (DKA), and hypoglycaemia or death within the subsequent year using multivariate Cox proportional
hazards models.
Results Not considering insulin and treatment for hypoglycaemia, the mean number of prescribed drugs was 4.00 (SD 4.35). The
proportion of individuals being prescribed five or more drugs at baseline consistently increased with age (proportion [95% CI]:
0–19 years 2.04% [1.60, 2.49]; 40–49 years 28.50% [27.08, 29.93]; 80+ years 76.04% [67.73, 84.84]). Controlling for age, sex,
area-based socioeconomic deprivation and health status, each additional drug at baseline was associated with an increase in the
hazard for hospitalisation for falls, hypoglycaemia and death but not for DKA admissions (HR [95% CI]: falls 1.03 [1.01, 1.06];
DKA 1.01 [1.00, 1.03]; hypoglycaemia 1.05 [1.02, 1.07]; death 1.04 [1.02, 1.06]). We found a number of drug classes to be
associated with an increased hazard of one or more of these adverse health outcomes, including antithrombotic/anticoagulant
agents, corticosteroids, opioids, antiepileptics, antipsychotics, hypnotics and sedatives, and antidepressants.
Conclusions Polypharmacy is common among the Scottish population with type 1 diabetes and is strongly patterned by
sociodemographic factors. The number of prescribed drugs and the prescription of particular high-risk drug classes are strong
markers of an increased risk of adverse health outcomes, including acute complications of diabetes.
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CSII Continuous subcutaneous insulin infusion
DKA Diabetic ketoacidosis
NHS National Health Service
SCI-Diabetes Scottish Care Information-Diabetes
SIMD Scottish Index of Multiple Deprivation
Introduction
Life expectancy has rapidly increased among general popula-
tions and among the population with type 1 diabetes [1]. Due
to improvements in the prevention and treatment of diabetes-
related complications, more individuals with type 1 diabetes
are living longer [2, 3]. However, the incidence of most
diabetes-related complications and non-communicable
diseases increases with age [4, 5]. The fact that more individ-
uals with type 1 diabetes are reaching older ages is therefore
accompanied by several challenges associated with
multimorbidity (the presence of two or more long-standing
chronic conditions) [6]. Two of these challenges are the
increasing prevalence of polypharmacy, often defined numer-
ically as being exposed to five or more drugs with potential for
drug–drug interactions [7], and the increasing number of indi-
viduals being exposed to drugs that are associated with an
increased risk of medication errors and adverse drug reactions
[8].
For general populations, the prevalence and risks of
polypharmacy and high-risk prescribing are relatively well
explored [9, 10]. Polypharmacy and the prescription of high-
risk drugs were shown to be strongly associated with an
increased risk of adverse health outcomes [11–13].
However, identifying the extent to which these risks reflect
direct drug effects, drug–drug interactions or the health condi-
tions for which drugs are prescribed is difficult in observation-
al studies [14]. Despite the complexity of disentangling direct
drug effects from confounding by indication, the potential
harm from polypharmacy and high-risk prescribing has led
to clinical recommendations to minimise the potential risks
in Scotland and the UK [15, 16].
For particular disease groups and subpopulations, includ-
ing individuals with type 2 diabetes, the prevalence of
polypharmacy and its association with adverse health
outcomes is increasingly recognised [17–20]. In contrast, very
little is known for the population with type 1 diabetes. This is
surprising, as the management of type 1 diabetes and its
complications often require early pharmacological interven-
tions, implying that individuals are often exposed to complex
medication regimes for a long period of time [21, 22].
Using data for the entire Scottish population with type 1
diabetes, we mapped the number of prescribed drugs over age,
by sex and area-based socioeconomic deprivation on 1
January 2017. We then studied the association of each addi-
tional drug and the prescription of particular high-risk drugs at
baseline with the first hospital admission for falls, diabetic
ketoacidosis (DKA) and hypoglycaemia, or death within the
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subsequent 12 months. All studied outcomes represent impor-
tant endpoints: hospital admissions for DKA and
hypoglycaemia are among the major acute complications of
type 1 diabetes; falls and death are among the most reported
complications of polypharmacy among general populations.
In line with findings for general populations and individuals
with type 2 diabetes, we expected the number of prescribed
drugs among individuals with type 1 diabetes to increase with
age, to be higher among the female sex than the male sex, and
to be higher among individuals from more deprived areas.
Furthermore, we hypothesised that each additional drug and
the prescription of high-risk drug classes would be associated
with an increased hazard for hospitalisation for falls, DKA and
hypoglycaemia as well as death. These findings will provide
important evidence to improve appropriate prescribing among
individuals with type 1 diabetes.
Methods
Data sources We utilised pseudonymised, population-based
data, extracted from the Scottish Care Information-Diabetes
(SCI-Diabetes) collaboration database, which is a comprehen-
sive register of all individuals assigned a diagnosis of diabetes
in primary or secondary care in Scotland. In Scotland,
healthcare in the National Health Service (NHS) is free at
the point of delivery, providing a strong incentive to use
national screening programmes. The register captures more
than 99% of all diabetes cases in Scotland, covering clinical
data and information on prescriptions in primary care [23]. A
routinely applied algorithm, based on age, drug prescriptions
and clinical information on the type of diabetes, was used to
identify individuals with type 1 diabetes in the SCI-Diabetes
database [23]. Using the Community Health Index (CHI), a
unique personal identification number, records were linked
with information on hospital admissions from the Scottish
Morbidity Record 01 (SMR01) dataset provided by the
Information Services Division (ISD) of the NHS in
Scotland. In addition, we were able to link these data with
information on the date and the cause of death, provided by
National Records of Scotland (NRS).
Ethics approval Data and data linkage were set up with
approval from the Scottish A Research Ethics Committee
(ref 11/AL/0225), Caldicott Guardians and the Privacy
Advisory Committee (PAC - reference 33/11), now running
with approval from the Public Benefit and Privacy Panel for
Health and Social Care (PBPP - reference 1617-0147).
Study population Using the SCI-Diabetes database, we iden-
tified all individuals resident in Scotland, irrespective of their
age, who were alive and had a diagnosis of type 1 diabetes at
baseline, defined as 1 January 2017 (N = 28,245). For each
individual, we counted the total number of prescribed drugs
at baseline. Identical chemical substances, identified using the
seventh digit of the Anatomical Therapeutic Chemical
Classification System (ATC) of the WHO, were counted as
one drug [24]. Individuals with type 1 diabetes require insulin,
which is often prescribed together with drugs to manage
hypoglycaemia. Insulins, glycogenolytic hormones and
carbohydrates were not considered when counting the number
of prescribed drugs. In addition, we did not count devices such
as insulin pumps, flash monitors or needles.
We also examined whether individuals were prescribed
high-risk drugs. We decided to focus on those second- and
third-level ATC classes that were consistently reported to be
strongly associated with an increased risk of serious medica-
tion errors and adverse drug reactions, leading to hospital
admissions, disabilities or death [8, 25, 26]. While the use of
such drugs can of course be clinically appropriate, it is recom-
mended that these drug classes are critically reviewed period-
ically by the handling practitioner according to the recent
Scottish Polypharmacy and Appropriate Prescribing
Guidelines [15]. From a total number of 4747 unique ATC
codes, 769 (16.20%) unique ATC codes were captured as
high-risk drugs.
We used the Scottish Index of Multiple Deprivation
(SIMD) 2016 as an area-based measure of socioeconomic
deprivation. The SIMD is an area-level index that captures
social deprivation across multiple aspects of life, including
unemployment, income, education and crime rates at an indi-
vidual’s place of residence [27].
Measures of baseline characteristics for the study popula-
tion were identified within a 2 year window prior to baseline.
If multiple measurements were available, the measurement
closest to baseline was used. These measures were mainly
recorded in primary care and included diabetes duration,
HbA1c, systolic BP, diastolic BP, HDL-cholesterol, LDL-
cholesterol, total cholesterol, BMI, diabetic foot risk score,
retinopathy grading, eGFR, smoking status, and whether indi-
viduals used continuous subcutaneous insulin infusion (CSII).
The diabetic foot risk score reflects the maximum score of
either the left or the right foot. The retinopathy grading is
based on a score combining the maximum grading of each
eye. Measures of eGFR were adjusted for individuals receiv-
ing renal replacement therapy and categorised as <30
(ml min−1 [1.73 m]−2).
In addition, we obtained information on whether individuals
were previously admitted to hospital for CVD, hypoglycaemia
and DKA using all available information on hospital admis-
sions. We obtained information on the number of hospital
admissions within the 2 year period prior to baseline, not
considering admissions for DKA and hypoglycaemia.
The daily dose of insulin at baseline was conceptualised as
the mean daily dose of insulin per day within a 360 day
window ranging from 180 days before baseline to 180 days
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after baseline. For each individual, we combined information
on quantity, pack size and strength of all insulin prescriptions to
estimate the total amount of issued insulin within this 360 day
window. We then assumed that 20% of all prescribed insulin is
not taken due to damage, loss, a passed expiry date or deviance
from the established treatment regimen. While no study has
quantified this ‘waste factor’ explicitly for the population with
type 1 diabetes in Scotland, we followed results discussed in the
literature [28]. We then divided the corrected, total amount of
issued insulin by the number of days individuals were observ-
able within this 360 day window. A small number of unrealis-
tically high and low daily doses of insulin were identified using
the 0.5% (left) and 1% (right) tails of a fitted log-normal distri-
bution, the shape of which described the original data best.
The insulin dose for all identified outliers and all missing
sociodemographic and health information at baseline were
imputed using multiple imputation methods, based on all
covariates presented in this study. An overview on the fraction
of all imputed missing data at baseline is provided in ESM
Table 1. Imputations were carried out using the R-package
Amelia (R version 3.6.0, Amelia version 1.7.6; downloaded
via https://cran.r-project.org/).
Statistical analysisWe used summary statistics to describe the
characteristics of the study population at baseline. In addition,
summary statistics were used to map the number of drugs at
baseline over age, sex and SIMD quintiles. We obtained 95%
CIs for prevalence estimates using Poisson-based bootstrapping.
We followed all 28,245 individuals for a maximum period
of 12 months to the end of 2017 and identified any first admis-
sion to hospital with falls, DKA and hypoglycaemia within
this period as primary or secondary diagnosis. The relevant
ICD-10 codes (http://apps.who.int/classifications/icd10/
browse/2016/en) are shown in ESM Table 2. In addition, we
identified any deaths among the study population registered in
Scotland. Individuals who did not experience the studied
outcome during the follow-up period were right-censored at
the end of follow-up or at the point in time they became unob-
servable. This implied that, for all studied outcomes other than
death, individuals were right-censored in case they died with-
out being previously admitted to hospital for falls, DKA or
hypoglycaemia.
We used Cox proportional hazards models to study the asso-
ciation between both the number of ‘each additional drug’ and
the prescription of specific high-risk drugs at baseline with the
first hospital admissions for falls, DKA and hypoglycaemia or
death within the subsequent 12 month period. For each
outcome, we modelled the effect of ‘each additional drug’
controlled for all clinical and sociodemographic covariates.
For each outcome, we estimated 14 models, one for each
high-risk drug class, to examine the effect of that particular drug
class adjusted for clinical and sociodemographic covariates and
number of additional drugs at baseline.
Regression results are presented as HRs. The δ-method
was used to obtain corresponding 95% CIs. Data preparation
and analyses were carried out with R (version 3.6.0).
The assumption of proportional hazards was examined
using Schoenfeld residuals. Results of this analysis are shown
in ESM Table 3 and indicate that the proportionality assump-
tion was violated globally only for the model ‘Opioids–
Death’. For this model, we provided the HR from the Cox
model and a corresponding OR obtained from a logistic
regression; these were very similar in size.
Sensitivity analysesWe modelled the effect of ‘each addition-
al drug’ at baseline as a linear term. However, it is possible
that the effect of the number of drugs on the hazard is not
linear (e.g. there could be threshold numbers of drugs above
which risk increases). Therefore, in a sensitivity analysis, we
examined the partial effects of the number of drugs on the
hazard rate for all four outcomes. We re-ran all presented
models but specified the variable ‘each additional drug’ using
the most flexible form of penalised B-splines [29].
We investigated whether the effect of the number of drugs
on the hazard rate varied over age. We estimated the effect of
the number of drugs separately for the age groups 0–49 years,
50–69 years and 70+ years. In addition, we tested an interac-
tion effect between the number of drugs and age.
Results
Health profile of the study population An overview of the
study population is provided in Table 1. We studied 28,245
individuals with type 1 diabetes at baseline, of which 15,731
were male (55.69%) and 12,514 were female (44.31%). The
mean age was 42.31 years (SD 18.32) and the mean HbA1c
was 70.54 mmol/mol (SD 17.90) (8.60% [SD 3.79]). The
mean diabetes duration was 20.64 years (SD 13.87). Of all
studied individuals, 18.66% were previously admitted to
hospital for CVD, 18.70% for hypoglycaemia and 37.56%
for DKA. Among the study population, 34.95% were diag-
nosed with a mild or moderate retinopathy and 27.44% were
diagnosed with maculopathy or pre- or proliferative retinopa-
thy. Active ulcers or amputations were present among 7.81%
of all individuals. We found that 45.79% were current or
previous smokers and that 13.34% used a device for CSII
therapy.
Not considering insulin and treatment for hypoglycaemia,
the mean number of prescribed drugs was 4.00 (SD 4.35). The
most frequently prescribed ATC groups were cardiovascular
system drugs (45.11% prevalence), nervous system drugs
(37.10%) and alimentary tract and metabolism drugs
(31.32%).
Table 2 provides an overview of the prevalence of all stud-
ied high-risk drug classes at baseline. Out of all the 28,245
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individuals, 13,204 (46.75%) were prescribed at least one of
the drugs listed in Table 2. Among those, the most frequent
drug classes were antidepressants (n = 5384 [19.06%]),
diuretics (n = 4462 [15.8%]) and calcium channel blockers
(n = 2977 [10.54%]).
Prevalence of polypharmacy Figure 1 illustrates the number of
prescribed drugs (not considering insulin and treatment for
hypoglycaemia) by age at baseline. The prevalence of individ-
uals prescribed five or more drugs increased from 2.04%
(95% CI 1.60, 2.49) among individuals aged 0–19 years to
28.50% (95%CI 27.08, 29.93) among those aged 40–49 years
and 76.04% (95%CI 67.73, 84.84) among those aged 80 years
and older.
A more detailed overview of prescribed medication
patterns over age and by sex is given in ESM Fig. 1 and
ESM Table 4. ESM Fig. 2 provides an overview on age
patterns across the most frequently prescribed first-level
ATC groups.
The number of prescribed drugs differed by sex and area-
based socioeconomic deprivation. Figure 2 shows the preva-
lence of individuals on five or more drugs, not considering
insulin and treatment for hypoglycaemia, over age and by
SIMD quintile. In both sexes, the prevalence of individuals
on five or more drugs was higher among individuals from
more deprived areas than among those from less deprived
areas; this difference was more marked in the female sex than
in the male sex. As an illustration, the prevalence of individ-
uals in SIMD quintile 5 (least deprived area) aged 40–49 years
prescribed five or more drugs was 21.14% (95% CI 17.22,
25.24) among the male sex and 29.31% (95% CI 24.35,
34.52) among the female sex. The corresponding prevalence
in individuals in SIMD quintile 1 (most deprived area) was
42.07% (95% CI 37.26, 47.02) among the male sex and
58.69% (95% CI 51.69, 65.68) among the female sex.
Association with adverse health outcomes Within the study
period, we observed 308 admissions for falls, 1450 admis-
sions for DKA and 497 admissions for hypoglycaemia. In
addition, we observed 431 deaths. A detailed overview of
the number of events over age is provided in ESM Table 5.
Table 3 presents results of all estimated Cox models. The
number of additional drugs at baseline (not considering insu-
lin and treatment for hypoglycaemia) was associated with a
significant increase in the hazard for hospital admissions for
falls, hypoglycaemia and death but not admissions for DKA
(HR [95% CI]: falls 1.03 [1.01, 1.06]; DKA 1.01 [1.00, 1.03];
hypoglycaemia 1.05 [1.02, 1.07]; death 1.04 [1.02, 1.06]).
Furthermore, we found several of the potentially high-risk
drug classes to be associated with an increased hazard of
adverse health outcomes. Antithrombotic/anticoagulant
agents were significantly associated with hospital admissions
for DKA (HR 1.26 [95%CI 1.03, 1.50]), while corticosteroids
were associated with an increased hazard for admissions for
hypoglycaemia (HR 1.73 [95% CI 1.38, 2.07]). In particular,
we found nervous system drugs to be associated with an
increased hazard for adverse health outcomes. For example,
antidepressants were associated with hospital admissions for
falls (HR 1.96 [95% CI 1.70, 2.21]), DKA (HR 1.30 [95% CI
Table 1 Overview of individuals with type 1 diabetes in Scotland on 1
January 2017
Characteristic Value
Male sex, n (%) 15,731 (55.69)
Female sex, n (%) 12,514 (44.31)
Age, years 42.31±18.32
No. of additional drugs 4.00±4.35
No. of main ATC groups 2.44±2.14
Diabetes duration, years 20.64±13.87
HbA1c, mmol/mol 70.54±17.90
HbA1c, % 8.60±3.79
Adjusted daily dose of insulin, U 62.75±31.26
Systolic BP, mmHg 128.50±17.09
Diastolic BP, mmHg 74.20±10.42
HDL-cholesterol, mmol/l 1.53±0.46
LDL-cholesterol, mmol/l 2.54±0.91
Total cholesterol, mmol/l 4.66±1.06
BMI, kg/m2 26.53±5.65
No. of previous admissions
excluding hypoglycaemia /
DKA in the 2 years prior to baseline
1.11±3.04
Previous CVD admission, n (%) 5271 (18.66)
Previous DKA admission, n (%) 10,608 (37.56)
Previous hypoglycaemia admission, n (%) 5283 (18.70)
CSII therapy, n (%) 3768 (13.34)
Ever smoker, n (%) 12,933 (45.79)
CKD-EPI eGFR, n (%)
≥90 ml min−1 [1.73 m]−2 18,695 (66.19)
60–89 ml min−1 [1.73 m]−2 7034 (24.90)
30–59 ml min−1 [1.73 m]−2 1876 (6.64)
<30 ml min−1 [1.73 m]−2 640 (2.27)
Retinopathy / maculopathy, n (%)
None 10,624 (37.61)
Mild / moderate 9871 (34.95)
Maculopathy / pre- or proliferative retinopathy 7750 (27.44)




Active ulcer / amputation 2207 (7.81)
First-level ATC groups, n (%)
ATC A: Alimentary tract and metabolism 8847 (31.32)
ATC B: Blood and blood forming organs 8147 (28.84)
ATC C: Cardiovascular system 12,742 (45.11)
ATC D: Dermatologicals 3138 (11.11)
ATC G: Genito urinary system and sex hormones 5038 (17.84)
ATC H: Systemic hormonal preparations, excluding
sex hormones and insulins
4700 (16.64)
ATC J: Anti-infective for systemic use 4346 (15.39)
ATC L: Antineoplastic and immunomodulating agents 849 (3.01)
ATC M: Musculoskeletal system 2453 (8.68)
ATC N: Nervous system 10,478 (37.10)
ATC P: Antiparasitic products, insecticides, repellents 570 (2.02)
ATC R: Respiratory system 5464 (19.35)
ATC S: Sensory organs 1892 (6.70)
ATC V: Various 254 (0.90)
Data are presented as mean±SD or n (%)
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1.16, 1.43]) and death (HR 1.26 [95% CI 1.04, 1.47]). In
addition, antipsychotics were associated with an increased
hazard for hospital admissions for DKA (HR 1.45 [95% CI
1.21, 1.69]), hypoglycaemia (HR 1.45 [95% CI 1.05, 1.85])
and death (HR 2.68 [95%CI 2.33, 3.03]) and anxiolytics were
associated with hospital admissions for hypoglycaemia (HR
1.40 [95% CI 1.01, 1.79]).
Results of sensitivity analyses We assumed the effect of the
number of drugs on a hazard to be linear and examined this
assumption. Results of this analysis are shown in ESM Fig. 3
and suggested no departure from this.
We also investigated whether the effect of the number of
drugs on the hazard for all four studied outcomes varied over
age. Results of this analysis are shown in ESM Table 6 and
indicate that the effect varied across age groups. As an example,
while the effect of the number of drugs was not significantly
associated with DKA admissions when considering all age
groups, the effect was significant among the 50–69 years age
group. However, the effect of the number of drugs on fall admis-
sions was significant when all age groupswere considered, while
the effect was not significant among the age group 0–49 years.
Furthermore, we examined the significance of an interac-
tion term between the number of drugs and age.We found this
Table 2 Individuals with type 1
diabetes in Scotland on 1 January
2017 on all studied high-risk drug
classes and mean number of
prescribed drugs among those
individuals who were prescribed
this particular high-risk drug class
Drug class Absolute number Percentage Mean
A10B: Blood-glucose-lowering drugs, excluding insulin 1945 6.89 1.09
B01A: Antithrombotic/anticoagulant agents 1448 5.13 1.02
C03: Diuretics 4462 15.80 1.19
C07: Beta blockers 2315 8.20 1.00
C08: Calcium channel blockers 2977 10.54 1.00
H02: Corticosteroids 917 3.25 1.89
L04A: Immunosuppressants 545 1.93 1.35
M01A: Nonsteroidal anti-inflammatory agents 1751 6.20 1.04
N02A: Opioids 1602 5.67 1.09
N03A: Antiepileptics 2250 7.97 1.11
N05A: Antipsychotics 613 2.17 1.14
N05B: Anxiolytics 620 2.20 1.03
N05C: Hypnotics and sedatives 599 2.12 1.03


































Fig. 1 Prescribed drugs in the
Scottish population with type 1
diabetes on 1 January 2017, not
considering insulin and treatment
for hypoglycaemia
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effect to be only significant for DKA admissions. While the
main effect of the number of drugs was not significant, the
direction of the interaction effect suggested that the effect of
each additional drug increased the hazard rate for DKA admis-
sions with increasing age.
Discussion
Principle findings This analysis shows the high prevalence of
polypharmacy and high-risk drug prescribing among the
Scottish population with type 1 diabetes. Not considering insu-
lin and treatment for hypoglycaemia, roughly one-quarter of
individuals were taking five or more drugs by 40 years of
age. By 60 years of age, around half of all individuals were
taking five or more drugs. The levels of polypharmacy
observed in this study are higher than those reported for the
general Scottish population [9, 30], even when excluding insu-
lin and drugs for the management of hypoglycaemia.
We found the prevalence of polypharmacy among individ-
uals with type 1 diabetes to be higher among the female sex
than among the male sex. Similar patterns have been reported
for general populations. A higher number of prescriptions
among the female sex may partly reflect that they are more
likely to live longer, accumulating a larger number of chronic
and disabling conditions [31]. In addition, our findings on the
prevalence of polypharmacy mirror patterns observed in the
general Scottish population with respect to differences by
area-based socioeconomic deprivation [30, 32]. We found
the frequency of individuals on five or more drugs to be
substantially higher in more deprived areas than in less
deprived areas. This may be explained by higher prevalence
of underlying health conditions for which these drugs are
prescribed, since many conditions show socioeconomic gradi-
ents, but may also in part reflect over-prescribing.
We found each additional drug at baseline to be associated
with an increase in the hazard for hospitalisation for falls and
hypoglycaemia, and death over 1 year follow-up. We further-
more found several potentially high-risk drug classes to be
associated with an increased hazard for adverse health
outcomes. Such associations may reflect risks for the conditions
for which these drugs are prescribed or may be a consequence
of direct drug effects. Our focus was not on differentiating
between these two explanations but on highlighting the extent
of polypharmacy and the potential for adverse health outcomes
following from this. At the very least, polypharmacy and high-
risk prescribing are important markers of elevated risk of the
outcomes studied in this population, irrespective of causality.
Comparisons with previous studies To our knowledge, no
previous study has explicitly addressed the association
between polypharmacy and particular high-risk drug classes
with adverse health outcomes among individuals with type 1
diabetes. One explanation for this lack of research could be
that guideline recommendations typically consider
polypharmacy among individuals with type 1 and type 2
diabetes unavoidable and clinically beneficial [33, 34].
Indeed, polypharmacy and the prescription of particular
high-risk drug classes can be appropriate [15].
The associations with health outcomes we report echo
results on the association of polypharmacy and high-risk
drugs with adverse health outcomes among general popula-
tions and, with respect to polypharmacy, among individuals

























































































Fig. 2 Prevalence of individuals
prescribed five or more drugs in
the Scottish population with type
1 diabetes on 1 January 2017 for
age categories, by sex and SIMD,
not considering insulin and
treatment for hypoglycaemia
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have shown that both factors, polypharmacy and high-risk
prescribing, were associatedwith falls, incontinence, delirium,
depression and insomnia, resulting in elevated hospitalisation
and mortality rates.
Strengths and limitations In this cohort study, we used
routinely collected, electronic healthcare records covering
the entire Scottish population with type 1 diabetes. In contrast
to survey data, these data substantially reduce the risk of selec-
tion bias and loss to follow-up. In addition, information on
drug use from registers are not affected by recall bias of self-
or proxy-respondents, which have a significant impact on the
generalisability of findings investigating medication patterns
by age, sex and socioeconomic status [38].
Findings of this study are subject to limitations. Information
on prescriptions does not include information on whether drugs
were taken, sowe cannot directlymeasuremedication adherence.
In addition, the data only included drug prescriptions recorded in
general practice and do not cover any over-the-counter drugs or
drugs given in hospitals and social care facilities, possibly
resulting in an underestimation of drug exposure.
Healthcare in Scotland is free and universal at point of
delivery. The findings of this study might therefore not be
generalisable to healthcare contexts in which access to prima-
ry care is not free of charge and purchase of drugs requires
out-of-pocket expenditure.
The most important limitation is that the associations between
drugs and adverse health outcomes are likely to be subject to
confounding by indication. We have not attempted to construct
causal models or conduct propensity score adjustments in this
initial study of polypharmacy and high-risk prescribing. Such
causal analyses would require more detailed drug-by-drug anal-
ysis and access to all diagnostic codes assigned in primary care
that we do not currently have access to.
Practical implications This study highlights the prevalence of
polypharmacy among individuals with type 1 diabetes, and its
role as a potential marker of increased risk of adverse health
outcomes, such as hypoglycaemia. Our findings should
increase awareness of the potential risks that might flow from
polypharmacy. Number of drugs may be a useful proxy for
risk of adverse outcomes that could prompt clinicians to
review drug needs periodically.
With an observational study design, it is difficult to quantify
the extent to which polypharmacy-associated outcomes are
directly causal or reflect confounding by indication. Direct
effects of polypharmacy could arise from component single drug
adverse reactions, drug–drug interaction and drug–disease inter-
action as well as off-target effects on the nervous system (e.g.
anticholinergic or extrapyramidal effects) or cardiovascular
system (e.g. hypotension). All of these associations with
polypharmacy have been noted in other patient populations
[39]. Another mechanism of harm from polypharmacy is that
adherence to effective medications is known to fall proportional
to the number of prescribed drugs [40].
Table 3 HR (95% CI) derived from multivariate Cox proportional hazards models for factors associated with hospital admissions for falls, DKA,
hypoglycaemia and death among people with type 1 diabetes in Scotland in 2017
Variable Falls DKA Hypoglycaemia Death
Each additional druga 1.03 (1.01, 1.06) 1.01 (1.00, 1.03) 1.05 (1.02, 1.07) 1.04 (1.02, 1.06)
Drug classb
A10B: Blood-glucose-lowering drugs, excluding insulin 1.00 (0.57, 1.43) 0.75 (0.46, 1.05) 0.74 (0.29, 1.18) 0.60 (0.16, 1.03)
B01A: Antithrombotic/anticoagulant agents 1.22 (0.90, 1.54) 1.26 (1.03, 1.50) 1.30 (1.00, 1.60) 0.89 (0.64, 1.14)
C03: Diuretics 1.08 (0.80, 1.36) 0.88 (0.71, 1.05) 0.88 (0.63, 1.13) 1.04 (0.81, 1.26)
C07: Beta blockers 1.04 (0.73, 1.35) 0.93 (0.71, 1.14) 1.02 (0.74, 1.31) 1.02 (0.78, 1.25)
C08: Calcium channel blockers 0.92 (0.62, 1.21) 1.09 (0.88, 1.30) 0.66 (0.36, 0.97) 0.71 (0.47, 0.95)
H02: Corticosteroids 0.89 (0.36, 1.41) 1.09 (0.82, 1.36) 1.73 (1.38, 2.07) 1.32 (0.95, 1.69)
L04A: Immunosuppressants 0.56 (0.00, 1.29) 0.76 (0.35, 1.18) 0.69 (0.14, 1.23) 0.66 (0.15, 1.16)
M01A: Nonsteroidal anti-inflammatory agents 1.13 (0.75, 1.52) 1.06 (0.85, 1.27) 0.78 (0.40, 1.16) 0.60 (0.17, 1.02)
N02A: Opioids 1.25 (0.90, 1.60) 1.12 (0.92, 1.32) 0.75 (0.42, 1.07) 1.66 (1.37, 1.95)c
N03A: Antiepileptics 1.29 (0.97, 1.61) 1.17 (1.00, 1.34) 1.10 (0.83, 1.36) 0.79 (0.51, 1.06)
N05A: Antipsychotics 1.22 (0.66, 1.77) 1.45 (1.21, 1.69) 1.45 (1.05, 1.85) 2.68 (2.33, 3.03)
N05B: Anxiolytics 1.49 (1.00, 1.98) 0.99 (0.70, 1.28) 1.40 (1.01, 1.79) 1.35 (0.94, 1.77)
N05C: Hypnotics and sedatives 1.61 (1.15, 2.07) 1.17 (0.90, 1.44) 1.06 (0.65, 1.47) 1.74 (1.39, 2.08)
N06A: Antidepressants 1.96 (1.70, 2.21) 1.30 (1.16, 1.43) 1.16 (0.94, 1.38) 1.26 (1.04, 1.47)
a Controlled for all covariates with the exception of exposure to all specific high-risk drug classes
b Controlled for all covariates, including the number of additional drugs at baseline, but not for the exposure to all other specific high-risk drug classes
c Value forModel ‘N02A: Opioids –Death’ reports OR and 95%CI from logistic regression. Corresponding value from the Coxmodel: 1.69 (1.42, 1.96)
1316 Diabetologia (2021) 64:1309–1319
People with type 1 diabetes attending many different
specialist clinics may have new drugs added for specific prob-
lems without adequate consideration given to their full range
of health conditions and existing medication regimens. In
current guidelines, such as the ‘Realistic Prescribing’
programme in Scotland [15], patient-centred medication
reviews have been proposed as the means to reduce prescrib-
ing harm in the general population [41]. It would seem
prudent that people with type 1 diabetes who are on ten or
more drugs, or individuals approaching the end of life, should
have such reviews conducted as is recommended for the
general population. Recent, in-depth qualitative studies have
highlighted that in practice patient-centred reviews often do
not involve the patients and do not lead to change in prescrib-
ing for complex reasons including primary care physician time
and reluctance to contradict specialist prescribing [42].
Therefore the impact of patient-centred reviews on prescribing
levels and health outcomes is mixed [43–45].
Our study highlights the need for a patient-centred medica-
tion review to be tailored specifically for the population with
type 1 diabetes, who are at risk of a specific set of adverse
outcomes. Intervention studies, aimed at improving prescrib-
ing in the context of type 1 diabetes, are needed.
Conclusion Our findings indicate that polypharmacy is
common and strongly patterned by sociodemographic factors
among the population with type 1 diabetes in Scotland. The
number of prescribed drugs and the prescription of high-risk
drug classes are strong risk markers for adverse health
outcomes, including acute complications of diabetes.
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